EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Cardiovascular and diabetes outcomes after metabolic bariatric surgery versus obesity management medications: nationwide overlap-weighted cohort study of 379 858 patients

Andrew P Gillikin, Emily P Rabinovich, Abdelrahman A Nimeri, Ali Tavakkoli, Thomas H Shin

British Journal of Surgery · 2026-10-31 · 113 (11)

DOI: 10.1093/bjs/znag139 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Metabolic bariatric surgery (MBS) and incretin-based therapy (IBT) are effective treatments for obesity and type 2 diabetes (T2D). However, their comparative effectiveness in current practice remains incompletely defined. Methods Adults aged ≥18 years with obesity and T2D who underwent MBS or initiated obesity management medications (OMMs) were identified. The median follow-up was 4.9 (interquartile range (i.q.r.) 3.6–6.7) years for MBS and 4.3 (i.q.r. 3.4–5.8) years for IBT. Overlap weighting balanced baseline covariates between groups. Five-year outcomes included nephropathy, retinopathy, major adverse cardiovascular events (MACE), and all-cause mortality. One-year outcomes included percentage total weight loss (%TWL) and rates of haemoglobin A1c (HbA1c) <6.5%. Results In total, 379 858 adults met the inclusion criteria (32 401 underwent MBS and 347 457 initiated OMMs). After overlap weighting, baseline covariates were well balanced. Compared with OMMs, MBS was associated with lower 5-year cumulative incidences of nephropathy (4.5% versus 8.3%; −3.8% points; HR 0.55 (95% c.i. 0.52 to 0.60)), retinopathy (3.6% versus 7.4%; −3.8% points; HR 0.60 (95% c.i. 0.55 to 0.65)), MACE (6.1% versus 8.1%; −2.0% points; HR 0.78 (95% c.i. 0.73 to 0.84)), and all-cause mortality (2.1% versus 3.7%; −1.6% points; HR 0.61 (95% c.i. 0.55 to 0.69)). At 1 year, the mean %TWL was greater after MBS (25.4% (95% c.i. 25.3% to 25.5%)) than after OMMs (6.4% (95% c.i. 6.3% to 6.5%)). Among patients with baseline HbA1c ≥6.5%, the proportion achieving HbA1c <6.5% at 1 year was higher after MBS (76.7% (95% c.i. 75.3% to 78.0%)) than after OMMs (47.2% (95% c.i. 46.2% to 48.1%); P < 0.001). Findings were consistent across agent-stratified, competing-risk, landmark, and no-censoring sensitivity analyses. Conclusion Among adults with obesity and T2D, MBS was associated with greater %TWL, higher glycaemic normalization, and lower 5-year risks of nephropathy, retinopathy, MACE, and all-cause mortality compared with real-world initiation of OMMs among patients in clinical equipoise, supporting the role of MBS as a durable therapy in multimodal obesity management.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →